3 news items
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
OCUP
VTRS
10 May 24
for the reimbursement of research and development services. During the first quarter of 2024 Ocuphire earned its first royalty payment in the amount of $3,000
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada
VTRS
15 Apr 24
A comprehensive patient support program, VIATRIS ADVOCATE™, offers services for patients including reimbursement
Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris
VTRS
11 Mar 24
of attorneys' fees and reimbursement of litigation expenses (including an award to Plaintiff) should be approved
- Prev
- 1
- Next